Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy

Tuberculosis

Volumn 89, Issue 1, 2009, Pages 91-94

  Buccheri, Simona ^a   Reljic, Rajko ^b   Caccamo, Nadia ^a   Meraviglia, Serena ^a   Ivanyi, Juraj ^c   Salerno, Alfredo ^a   Dieli, Francesco ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antibodies; Cytokines; Immunotherapy; Relapse; Tuberculosis

Indexed keywords

ALPHA CRYSTALLINE ANTIBODY; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN A ANTIBODY; INTERLEUKIN 4 ANTIBODY; ISONIAZID; NITRIC OXIDE; RECOMBINANT GAMMA INTERFERON; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BAGG ALBINO MOUSE; C57BL 6 MOUSE; HISTOLOGY; IMMUNOTHERAPY; INOCULATION; LUNG GRANULOMA; LUNG LAVAGE; LUNG TUBERCULOSIS; MORPHOMETRICS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSING TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ALPHA-CRYSTALLINS; ANIMALS; ANTIBODIES; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; COMBINED MODALITY THERAPY; IMMUNOGLOBULIN A; IMMUNOTHERAPY; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-4; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; TUBERCULOSIS, PULMONARY;

EID: 58149139046     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2008.09.001     Document Type: Article

References (32)

1. Cannetti G. Host factors and chemotherapy of tuberculosis. In: Barry III C.E. (Ed). Chemotherapy of tuberculosis (1965), Butterworth, London 175-191
2. Grange J. Immunotherapy of tuberculosis. Tubercle 71 (1970) 237-239
3. Venkataprasad N., Ledger P., and Ivanyi J. The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production. Int Arch Allergy Immunol 114 (1997) 23-29
4. Johnson J.L., Ssekasanvu E., Okwera A., Mayanja H., Hirsch C.S., Nakibali J.G., et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 168 (2003) 185-191
5. Mwinga A., Nunn A., Ngwira B., Chintu C., Warndorff D., Fine P., et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 360 (2002) 1050-1055
6. Lowrie D.B., and Silva C.L. Enhancement of immunocompetence in tuberculosis by DNA vaccination. Vaccine 18 (2000) 1712-1716
7. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., Colston M.J., Hewinson R.G., Moelling K., and Silva C.L. Therapy of tuberculosis in mice by DNA vaccination. Nature 400 (1999) 269-271
8. Ha S.J., Jeon B.Y., Kim S.C., Kim D.J., Song M.K., Sung Y.C., et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Ther 10 (2003) 1592-1599
9. Cardona P.J., Amat I., Gordillo S., Arcos V., Guirado E., Diaz J., et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23 (2005) 1393-1398
10. Turner J., Rhoades E.R., Keen M., Belisle J.T., Frank A.A., and Orme I.M. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 68 (2000) 1706-1709
11. Repique C.J., Li A., Collins F.M., and Morris S.L. DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 70 (2002) 3318-3323
12. Guirado E., Amat I., Gil O., Diaz J., Arcos V., Caceres N., et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 8 (2006) 1252-1259
13. Barnes P.F. Immunotherapy for tuberculosis: wave of the future or tilting at windmills?. Am J Respir Crit Care Med 168 (2003) 142-143
14. Who E. Report of the expert consultation on immunotherapeutic interventions for tuberculosis (2007), TRD/WHO, Geneva
15. Reljic R., Williams A., and Ivanyi J. Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?. Tuberculosis (Edinburgh) 86 (2006) 179-190
16. Buccheri S., Reljic R., Caccamo N., Ivanyi J., Singh M., Salerno A., et al. IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur J Immunol 37 (2007) 729-737
17. Reljic R., Clark S.O., Williams A., Falero-Diaz G., Singh M., Challacombe S., et al. Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection. Clin Exp Immunol 143 (2006) 467-473
18. Tjarnlund A., Rodriguez A., Cardona P.J., Guirado E., Ivanyi J., Singh M., et al. Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice. Int Immunol 18 (2006) 807-816
19. Medina E., and North R.J. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 93 (1998) 270-274
20. Cox J.H., and Ivanyi J. The role of host factors for the chemotherapy of BCG infection in inbred strains of mice. Apmis 96 (1988) 927-932
21. Cox J.H., Knight B.C., and Ivanyi J. Mechanisms of recrudescence of Mycobacterium bovis BCG infection in mice. Infect Immun 57 (1989) 1719-1724
22. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., and Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002) 4620-4627
23. Saukkonen J.J., Bazydlo B., Thomas M., Strieter R.M., Keane J., and Kornfeld H. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun 70 (2002) 1684-1693
24. Wallis R.S. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41 (2005) 201-208
25. Yuan Y., Crane D.D., and Barry III C.E. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 178 (1996) 4484-4492
26. Shi L., Jung Y.J., Tyagi S., Gennaro M.L., and North R.J. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci U S A 100 (2003) 241-246
27. Garbe T.R., Hibler N.S., and Deretic V. Response to reactive nitrogen intermediates in Mycobacterium tuberculosis: induction of the 16-kilodalton alpha-crystallin homolog by exposure to nitric oxide donors. Infect Immun 67 (1999) 460-465
28. Sherman D.R., Voskuil M., Schnappinger D., Liao R., Harrell M.I., and Schoolnik G.K. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A 98 (2001) 7534-7539
29. Pheiffer C., Betts J.C., Flynn H.R., Lukey P.T., and van Helden P. Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv. Microbiology (Reading, England) 151 (2005) 1139-1150
30. Abebe F., and Bjune G. The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guerin (BCG) vaccines: is there a link?. Clin Exp Immunol 145 (2006) 389-397
31. Dieli F., Taniguchi M., Kronenberg M., Sidobre S., Ivanyi J., Fattorini L., et al. An anti-inflammatory role for V alpha 14 NK T cells in Mycobacterium bovis bacillus Calmette-Guerin-infected mice. J Immunol 171 (2003) 1961-1968
32. Hernandez-Pando R., Aguilar D., Hernandez M.L., Orozco H., and Rook G. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-alpha and in the regulation of fibrosis. Eur J Immunol 34 (2004) 174-183